Team

Gemini Therapeutics' team was built for aldoxorubicin. It includes leaders who helped secure FDA approvals for Doxil, the approved liposomal doxorubicin product; helped shape FDA cardiac-safety standards; reviewed oncology NDAs and 505(b)(2) applications from inside FDA; and bring senior expertise across late-stage clinical development.

Founders

Diego Rey, PhD

CEO

Diego is a company builder focused on translating complex science into scalable healthcare products. He co-founded GeneWEAVE Biosciences, acquired by Roche, where he served as Chief Scientific Officer and helped advance the company's FDA-authorized infectious-disease diagnostic test. He also co-founded Endpoint Health, serving as CSO and board member, where he led a precision-medicine approach developing therapies for immune-mediated diseases. Diego was the first Y Combinator Visiting Partner focused on life sciences and healthcare.

Sant Chawla, MD

Founder

Dr. Chawla is a leading oncologist and founding investigator of SARC, the Sarcoma Alliance for Research through Collaboration. He heads the Sarcoma Oncology Center in Santa Monica and has more than three decades of experience leading clinical research in bone and soft-tissue sarcomas. Dr. Chawla has contributed to approval-enabling clinical programs for therapies including trabectedin and denosumab. His academic and clinical affiliations have included UCLA, USC, John Wayne Cancer Institute, Cedars-Sinai, Stanford, and MD Anderson.

Sytse Sijbrandij

Founder

Sid is an entrepreneur, company builder, and patient advocate. He co-founded GitLab and grew it into a multi-billion dollar public software company used by more than 30 million registered users. After his own osteosarcoma diagnosis, Sid applied a data-intensive approach to his own care helping make scientific advances rapidly accessible to patients. He is President and Director of the Sijbrandij Foundation and a General Partner at Even One Ventures, which builds biotechnology companies designed to turn promising science into personalized treatments.

Operating Team

Edward Schnipper, MD

Clinical Development

Ed is an oncology clinical-development leader with decades of experience advancing cancer therapies from clinical strategy through regulatory approval. Ed held senior clinical-development roles at Hoffmann-La Roche, SEQUUS, and ALZA, where he led the clinical development work behind Doxil's FDA approvals, the first liposomal doxorubicin-derivative approved to treat a solid tumor.

Adam George, PharmD

Regulatory

Adam is a regulatory affairs leader with deep FDA and industry experience across oncology drug development. A former FDA clinical reviewer in the Office of Hematology and Oncology Products and senior reviewer in the Office of Prescription Drug Promotion, Adam brings first-hand experience reviewing INDs and NDAs including 505(b)(2) submissions. He previously held senior regulatory roles at Teva Pharmaceuticals and PureTech Health.

Philip Sager, MD

Cardiovascular Safety

Philip is a cardiologist and electrophysiologist with deep expertise in cardiovascular safety assessment for drug development. He has held senior industry and academic roles, served in leadership roles related to ICH E14 and the Cardiac Safety Research Consortium, and is a past chair of the FDA Cardio-Renal Advisory Committee. He has advised industry and regulatory agencies on cardiovascular risk assessment across development-stage and approved products.

William Mikrut, MSc

Biometrics

Bill is a biometrics and biostatistics leader with over 30 years of experience supporting late-stage clinical development, including FDA interactions, Phase 3 trial design, integrated efficacy and safety analyses, and NDA submissions.

Joyce James, PhD

Clinical Pharmacology

Joyce is a clinical pharmacology leader with deep experience spanning PK/PD, ADME, bioanalytical strategy, and drug metabolism. She has led early-development and clinical-pharmacology functions at Odonate Therapeutics and Lyric Pharmaceuticals, held senior clinical pharmacology and DMPK roles at Ambit Biosciences and Cytokinetics, and previously served as a Research Fellow at Merck Research Laboratories.

Scott Rudge, PhD

CMC

Scott is a CMC and pharmaceutical operations leader with more than three decades of experience directing process engineering, process development, product development, technology transfer, validation, and manufacturing strategy for biopharmaceutical products. He co-founded RMC Pharmaceutical Solutions, later acquired by Syner-G BioPharma Group, and has built and led technical teams across the biopharmaceutical industry.

Michael Shuster, PhD, JD

Intellectual Property

Michael is a life sciences intellectual property attorney with deep experience advising pharmaceutical companies on patent strategy, portfolio analysis, diligence, prosecution, litigation, and transactional IP matters. Michael is a partner in Goodwin's Life Sciences group. Prior to joining Goodwin, Michael co-headed the Life Sciences group at Fenwick & West LLP. Michael supports Gemini Therapeutics' intellectual property strategy, including portfolio positioning, diligence, partnering, and transaction-related IP issues for aldoxorubicin.

Asher Rubin, JD

Corporate Counsel

Asher is a life sciences corporate and transactions attorney with extensive experience advising public and private biotechnology and pharmaceutical companies across financing, licensing, collaboration, joint venture, M&A, governance, and outside general counsel matters. A partner at Sidley Austin and co-leader of its global Technology and Life Sciences Transactions practice, Asher supports Gemini Therapeutics' corporate strategy, governance, partnering, and transaction execution for aldoxorubicin.